Market Cap 30.15B
Revenue (ttm) 0.00
Net Income (ttm) -1.13B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 2,514,400
Avg Vol 3,185,204
Day's Range N/A - N/A
Shares Out 212.60M
Stochastic %K 24%
Beta 1.41
Analysts Strong Sell
Price Target $180.05

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6801
Address:
700 Saginaw Drive, Redwood City, United States
PeterLynch_IsBack
PeterLynch_IsBack May. 11 at 2:09 AM
$RVMD mean ass stage 2 uptrend ai said some bullish targets in 400s on approval. I mean its pretty close to approval if it this stuff is all true: The Three Main Drivers of Institutional Interest "Unprecedented" Clinical Breakthrough (April 2026) The Data: In the Phase 3 RASolute 302 trial, daraxonrasib nearly doubled the overall survival of metastatic pancreatic cancer patients (13.2 months) compared to standard chemotherapy (6.7 months). The Impact: Pancreatic cancer is famously difficult to treat; these results represent a 60% reduction in the risk of death, which analysts have called "practice-changing".
0 · Reply
JuggernautRaider
JuggernautRaider May. 10 at 8:52 PM
$IMRX earnings coming monday 🤫 i tried to get @Duediligence20 to sell $PPBT and buy this when it was below a $1.25 last year; Tony is a friend but now I realize I should have had just bought more 😜 $RVMD better watch their ass 🚽 Immuneering is coming 🚊
1 · Reply
biolover
biolover May. 10 at 5:06 PM
0 · Reply
ErosROI
ErosROI May. 10 at 2:54 PM
$RVMD I love the fact that we're getting new fans in here
1 · Reply
MeanReverter_
MeanReverter_ May. 9 at 3:21 PM
$GOOGL portfolio breakdown is basically a live risk map of where smart capital thinks the next cycle is going Big weight concentration tells the story: $CME – 26% (rates + liquidity backbone of the system) $PL – 25% (geospatial / defense mapping layer) $ASTS – 19% (satellite-to-cell connectivity bet) Then the satellite exposure: $RVMD – 8% ARM – 7% FRSH – 3% PATH – 2% TEM – 2% GTLB – 2% PRME – 1% This isn’t a passive basket — it’s a highly directional bet on infrastructure, data flow, and next-gen connectivity rails. When one of the largest capital allocators leans this hard into frontier infrastructure + AI adjacency, it’s usually not random positioning — it’s narrative confirmation before price fully follows. Curious about the full approach?👉 Check the @MeanReverter_
0 · Reply
docsamiles
docsamiles May. 8 at 7:20 PM
$ERAS What is different between these drugs is the incidence and severity of drug rash. This is again seen with all three but the severity goes RVMD >> ERAS >> VSTM. For an example, see pictures of Ben Sasse. He's on $RVMD. The $RVMD and $ERAS drugs are indentical in cross reactivity to H-Ras as the binding site ligand is identical. The lower incidence and severity of rash seen with ERAS-0015 has to do with the increased potency relative to RVMD-6236 allowing doctors to use a lower dose. This in turn results in a lower exposure of the skin cells to the drug and less inhibition of H-ras (the mechanism of the rash). $VSTM's drug has a lower affinity for H-Ras resulting in even lower incidence of rash. This will ultimately be the marketing differentiator in the marketplace and why $ERAS will eventually pass $RVMD in sales. All three will sell a LOT of drug and make a lot of money. Remember though, the market's not always rational.
2 · Reply
Ro_Patel
Ro_Patel May. 8 at 6:24 PM
1 · Reply
BioRich
BioRich May. 8 at 6:12 PM
$XBI Whoa! Trump wants Makary out? FDA Commish sent walking? Honestly, I watched the White House News Conference regarding psychadelics a few weeks ago and Trump was clearly questioning why it's taking so long to get drugs to people that need it and promoted his "Right to Try" promotion. Makary didn't look happy. If I can find the video, I'll share it. But I had a feeling that wasn't going to end well. So who benefits now? $CAPR I think is the clearest winner. $IBRX? $RVMD? Who y'all thinking? Follow/Subscribe for more suggestions and perspective. Would love to hear yours as well. That's how we find these gems and learn. Let's make some (more) money. Cheers! https://www.bloomberg.com/news/articles/2026-05-08/trump-plans-to-fire-fda-s-marty-makary-after-tumult-at-agency?utm_source=website&utm_medium=share&utm_campaign=copy
3 · Reply
Jackie_O_
Jackie_O_ May. 8 at 5:08 PM
$RVMD Welcome Google 🤗
0 · Reply
MeanReverter_
MeanReverter_ May. 8 at 3:55 PM
$GOOGL latest 13F footprint is basically a live map of where smart capital is parking exposure heading into the next cycle. Top disclosed equity positions show a very deliberate mix of liquidity, compute infrastructure, and high-beta innovation: $CME ~$1.03B — liquidity backbone / macro derivatives engine $PL ~$985M — data + analytics layer $ASTS ~$741M — space connectivity optionality $RVMD ~$320M — biotech asymmetric exposure ARM ~$297M — compute architecture leverage FRSH, PATH, GTLB — enterprise software stack positioning plus smaller biotech + early-stage innovation names like TEM, PRME, BBIO, RLAY What stands out here isn’t any single holding — it’s the structure: a barbell between market infrastructure stability and long-duration innovation bets. This is how institutional capital quietly builds exposure into the next narrative cycle — not chasing momentum, but seeding optionality across multiple growth vectors. Curious about the full approach?👉 Check the @MeanReverter_
0 · Reply
Latest News on RVMD
Revolution Medicines Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 days ago

Revolution Medicines Earnings Call Transcript: Q1 2026


There's a Revolution in Cancer. But Can Big Pharma Afford It?

Apr 28, 2026, 5:30 AM EDT - 12 days ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?


This Pill May Help Pancreatic Cancer Patients Live Longer

Apr 15, 2026, 12:10 PM EDT - 25 days ago

This Pill May Help Pancreatic Cancer Patients Live Longer


Revolution Medicines files to sell $750M of common stock

2026-04-13T21:10:39.000Z - 27 days ago

Revolution Medicines files to sell $750M of common stock


Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025


Overlooked Stock: RVMD Sells After MRK Turns Away

Jan 26, 2026, 4:30 PM EST - 3 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK


Merck No Longer in Talks to Buy Revolution Medicines

Jan 25, 2026, 2:30 PM EST - 3 months ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK


AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 4 months ago

AbbVie Near Deal for Revolution Medicines

ABBV


Revolution Medicines Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings Call Transcript: Q3 2025


Revolution Medicines Transcript: Study Result

Sep 10, 2025, 5:00 PM EDT - 8 months ago

Revolution Medicines Transcript: Study Result


Revolution Medicines Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Revolution Medicines Earnings Call Transcript: Q2 2025


PeterLynch_IsBack
PeterLynch_IsBack May. 11 at 2:09 AM
$RVMD mean ass stage 2 uptrend ai said some bullish targets in 400s on approval. I mean its pretty close to approval if it this stuff is all true: The Three Main Drivers of Institutional Interest "Unprecedented" Clinical Breakthrough (April 2026) The Data: In the Phase 3 RASolute 302 trial, daraxonrasib nearly doubled the overall survival of metastatic pancreatic cancer patients (13.2 months) compared to standard chemotherapy (6.7 months). The Impact: Pancreatic cancer is famously difficult to treat; these results represent a 60% reduction in the risk of death, which analysts have called "practice-changing".
0 · Reply
JuggernautRaider
JuggernautRaider May. 10 at 8:52 PM
$IMRX earnings coming monday 🤫 i tried to get @Duediligence20 to sell $PPBT and buy this when it was below a $1.25 last year; Tony is a friend but now I realize I should have had just bought more 😜 $RVMD better watch their ass 🚽 Immuneering is coming 🚊
1 · Reply
biolover
biolover May. 10 at 5:06 PM
0 · Reply
ErosROI
ErosROI May. 10 at 2:54 PM
$RVMD I love the fact that we're getting new fans in here
1 · Reply
MeanReverter_
MeanReverter_ May. 9 at 3:21 PM
$GOOGL portfolio breakdown is basically a live risk map of where smart capital thinks the next cycle is going Big weight concentration tells the story: $CME – 26% (rates + liquidity backbone of the system) $PL – 25% (geospatial / defense mapping layer) $ASTS – 19% (satellite-to-cell connectivity bet) Then the satellite exposure: $RVMD – 8% ARM – 7% FRSH – 3% PATH – 2% TEM – 2% GTLB – 2% PRME – 1% This isn’t a passive basket — it’s a highly directional bet on infrastructure, data flow, and next-gen connectivity rails. When one of the largest capital allocators leans this hard into frontier infrastructure + AI adjacency, it’s usually not random positioning — it’s narrative confirmation before price fully follows. Curious about the full approach?👉 Check the @MeanReverter_
0 · Reply
docsamiles
docsamiles May. 8 at 7:20 PM
$ERAS What is different between these drugs is the incidence and severity of drug rash. This is again seen with all three but the severity goes RVMD >> ERAS >> VSTM. For an example, see pictures of Ben Sasse. He's on $RVMD. The $RVMD and $ERAS drugs are indentical in cross reactivity to H-Ras as the binding site ligand is identical. The lower incidence and severity of rash seen with ERAS-0015 has to do with the increased potency relative to RVMD-6236 allowing doctors to use a lower dose. This in turn results in a lower exposure of the skin cells to the drug and less inhibition of H-ras (the mechanism of the rash). $VSTM's drug has a lower affinity for H-Ras resulting in even lower incidence of rash. This will ultimately be the marketing differentiator in the marketplace and why $ERAS will eventually pass $RVMD in sales. All three will sell a LOT of drug and make a lot of money. Remember though, the market's not always rational.
2 · Reply
Ro_Patel
Ro_Patel May. 8 at 6:24 PM
1 · Reply
BioRich
BioRich May. 8 at 6:12 PM
$XBI Whoa! Trump wants Makary out? FDA Commish sent walking? Honestly, I watched the White House News Conference regarding psychadelics a few weeks ago and Trump was clearly questioning why it's taking so long to get drugs to people that need it and promoted his "Right to Try" promotion. Makary didn't look happy. If I can find the video, I'll share it. But I had a feeling that wasn't going to end well. So who benefits now? $CAPR I think is the clearest winner. $IBRX? $RVMD? Who y'all thinking? Follow/Subscribe for more suggestions and perspective. Would love to hear yours as well. That's how we find these gems and learn. Let's make some (more) money. Cheers! https://www.bloomberg.com/news/articles/2026-05-08/trump-plans-to-fire-fda-s-marty-makary-after-tumult-at-agency?utm_source=website&utm_medium=share&utm_campaign=copy
3 · Reply
Jackie_O_
Jackie_O_ May. 8 at 5:08 PM
$RVMD Welcome Google 🤗
0 · Reply
MeanReverter_
MeanReverter_ May. 8 at 3:55 PM
$GOOGL latest 13F footprint is basically a live map of where smart capital is parking exposure heading into the next cycle. Top disclosed equity positions show a very deliberate mix of liquidity, compute infrastructure, and high-beta innovation: $CME ~$1.03B — liquidity backbone / macro derivatives engine $PL ~$985M — data + analytics layer $ASTS ~$741M — space connectivity optionality $RVMD ~$320M — biotech asymmetric exposure ARM ~$297M — compute architecture leverage FRSH, PATH, GTLB — enterprise software stack positioning plus smaller biotech + early-stage innovation names like TEM, PRME, BBIO, RLAY What stands out here isn’t any single holding — it’s the structure: a barbell between market infrastructure stability and long-duration innovation bets. This is how institutional capital quietly builds exposure into the next narrative cycle — not chasing momentum, but seeding optionality across multiple growth vectors. Curious about the full approach?👉 Check the @MeanReverter_
0 · Reply
MeanReverter_
MeanReverter_ May. 8 at 3:39 PM
$GOOGL just put its hand on the table — and the market finally sees how the positioning is stacked under the surface. Latest disclosed portfolio breakdown shows a very intentional, high-conviction tilt into infra + next-gen platforms: $CME ~26% — liquidity + derivatives backbone $PL ~25% — data/AI intelligence layer $ASTS ~19% — space-based connectivity optionality $RVMD ~8% — biotech asymmetry bet ARM ~7% — compute architecture exposure FRSH ~3% — SaaS workflow layer PATH ~2% — automation transition bet TEM ~2% — emerging biotech optionality GTLB ~2% — dev infra + code ecosystem PRME ~1% — early-stage conviction lottery This isn’t a “diversified basket” — it’s a mapped exposure to where digital + AI + compute convergence is heading. Big picture: capital isn’t chasing narratives anymore, it’s clustering around infrastructure control points. And $GOOGL is quietly positioned across multiple layers of that stack. Curious about the full approach?👉 Check the @MeanReverter_
0 · Reply
BioRich
BioRich May. 8 at 3:01 PM
$CADL $TGTX $IBRX $RVMD $TLSA Who gets the BO first? My thoughts: 1) TGTX 2) RVMD 3) IBRX 4) CADL 5) TLSA Wouldn't be surprised to see BO news on any of these though. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
6 · Reply
flabb
flabb May. 8 at 2:58 PM
$RVMD 142.27 added becuase what is 4 points down not a big deal to catch that 138.35 if she goes to 146.37 from here . good to go.
0 · Reply
flabb
flabb May. 8 at 1:45 PM
$RVMD filled 29.56 on the opening and is now climnbing . $AISP 2.43 filled
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 1:44 PM
Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: PayPay Corp (Tokyo-listed) - 3,125,000 $PL - 35,248,893 $PRME - 16,562,498 $RLAY - 1,564,173 $RVMD - 3,292,525 $SANA - 2,812,500 Google’s Q1 13F is here: Fintech, Real-time Earth, and Gene Editing! The 3.1M share stake in PayPay is a major power move into the East Asian payment ecosystem. Meanwhile, holding 35M shares of $PL (Planet Labs) signals that Google is weaponizing satellite data to give Gemini AI a "God’s eye view" of global logistics. Heavy bets on $PRME and $RVMD also prove that AI-driven oncology and gene editing are now core to Alphabet’s "Other Bets." Do you think the synergy between satellite data and fintech will lead to a breakthrough in 2026? Which of these strategic pivots are you most bullish on?
1 · Reply
flabb
flabb May. 8 at 12:48 PM
$RVMD i have to say has a shot at the 138.35 on the opening so if you like this soldier set your limit order there and if it goes lower add a share or two. I'll be accumulating until she bottoms but it wouldn't suck to catch the 138.35 order.
1 · Reply
flabb
flabb May. 8 at 11:09 AM
$RVMD 142.15 limit order in
1 · Reply
elmono
elmono May. 8 at 8:08 AM
$VSTM starts 3 registrational trials in mid 2026. Not too shabby. Q1 revs slightly under expectations but they are seeing demand pick up in Q1, so expect a banner Q2. Data at ASCO will be interesting but the big releases are coming later. Good they continue to believe in best in class efficacy at the 900 dose….bodes well. Market response as always negative but the valuation at 500 million extremely compelling compared to $ERAS and $RVMD . All it takes is 1 good read out at pivotal dose.
4 · Reply
flabb
flabb May. 7 at 6:57 PM
$DVLT added .49 $KSCP 3.03 $RVMD 143.35 $CLF 10.64 $PLUG 3.08 and 3.0 7 added and still adding each as power comes in while we move higher
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 7 at 4:38 PM
$MRK $RVMD $SLS A pancreatic cancer pill just sent a $19B biotech to $26B in 4 hours. A few weeks ago, Revolution Medicines reported Phase 3 results for daraxonrasib in metastatic pancreatic cancer. The drug nearly doubled overall survival vs. chemo and cut the risk of death by 60%. Their stock surged to $26B in a single session. Pancreatic cancer is one of the toughest ones. 13% five-year survival, RAS mutations in ~90% of cases. For decades, RAS was called "undruggable." Daraxonrasib hits multiple RAS variants at once, which makes it more effective. Merck walked away from acquiring RVMD at ~$30B in January due to the price. After these results, that's probably one of the most expensive "no" decisions in pharma this year.
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 7 at 4:36 PM
$SLS $MRK $RVMD RVMD MC is now $30 Billion plus. MRK passed at $30 Billion. SLS up Next. Before data Public $20 Billion after Data Bidding war= $40 Billion + SLS GPS CURATIVE in 20+ WT1 cancer types. ✌️❤️‍🩹🙏
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 7 at 3:19 PM
$SLS $RVMD $MRK Merck already lost RVMD deal and they are kicking themselves after the recent pancreatic cancer data the MC is above Merck’s offer to buy RVMD for $30 Billion. Merck is not making that mistake again. ✌️🙏❤️‍🩹
1 · Reply